Navigation Links
Valeant Pharmaceuticals Reports 2013 Third Quarter Financial Results
Date:10/31/2013

n, up 74% compared to the third quarter of 2012. Same store organic product sales growth for Legacy Valeant was 7%, excluding the impact of the genericization of the Zovirax franchise, Retin-A Micro and BenzaClin. These products accounted for approximately $100 million in lost sales as compared to the prior year.

Valeant's Developed Markets revenue was $1.14 billion, up 77% as compared to the third quarter of 2012. This increase was primarily led by the acquisition of Bausch + Lomb, which was completed on August 5, 2013. Same store organic product sales growth was 4%, excluding the impact of the genericization of the Zovirax franchise, Retin-A Micro (unexpectedly launched following Valeant's second quarter financial results conference call) and BenzaClin. The growth in the Developed Markets was driven by continued improvement in many of our Dermatology prescription brands, our aesthetics and oral health portfolios, our orphan drug products and CeraVe.

Valeant's Emerging Markets revenue was $399 million, up 68% as compared to the third quarter of 2012.  This increase was also primarily led by the acquisition of Bausch + Lomb.  Total same store sales growth was 14% for the segment, driven by continued strong growth in all of our emerging markets, particularly Poland, Russia, South East Asia and South Africa. 

Since the transaction closed on August 5, 2013, Bausch + Lomb has delivered a same store sales organic growth rate of 10% as compared to the prior year, driven primarily by the U.S. and Emerging Market operations.

The Company reported a net loss of $973 million for the third quarter of 2013, or a loss of $2.92 per share due to the following one-time items: 1) impairment charges of $645 million for ezogabine/retigabine immediate-release formulation and the discontinuation of the modified-release formulation; 2) agreement to pay Anacor Pharmaceuticals $142.5 million to settle all outstanding existing and future claims rel
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 ... Überwachungssystem für kongestive Herzinsuffizienz (CHF) in seiner ...     Die ... neuartiges Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz ... sie ein Finanzierungsvorhaben über 5 Mio. USD ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
(Date:2/26/2015)... Feb. 26, 2015  AbbVie (NYSE: ... studies in its neuroscience and oncology development programs ... th American Academy of Neurology annual meeting ... April 18-25. The accepted abstracts feature results from ... to investigational treatments in AbbVie,s pipeline. Presentations will ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... VEGAS, Jan. 9, 2012 BASIS Science, Inc. ( www.mybasis.com ... and health tracker, the Basis™ B1 band, will be demoing ... showing its web-based personal dashboard for the first time. The ... people information about their everyday health and wellness. ...
... the nation,s largest independent specialty pharmacy in the ... rights from Regeneron for its new drug EYLEA™ ... 2011, EYLEA (aflibercept) Injection was approved by the ... the treatment of neovascular (wet) age-related macular degeneration ...
Cached Medicine Technology:BASIS Science to Demo Basis Band at 2012 International CES; Reveals Design of Web Dashboard 2Diplomat Specialty Pharmacy to Provide Specialty Pharmacy Services for EYLEA™ (aflibercept) Injection 2
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 A ... found a correlation between men who cycle on a regular ... overall health, the study suggests that the more hours per ... to develop prostate cancer, leading to an increased importance on ... it allows physicians to look more closely at patents’ risk ...
(Date:2/27/2015)... MD (PRWEB) February 27, 2015 ... (Meso Foundation) and the National Cancer Institute (NCI) ... Mesothelioma at the National Institutes of Health (NIH), ... one part is dedicated to medical professionals and ... is directed to the general public, including patients, ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Pipette.com announces ... 2 , price is only valid until the end ... technicians looking for a vortex mixer that allows for ... was founded in 1954 and is headquartered in Bohemia, ... & shakers, as well as other rockers, incubators, and ...
(Date:2/27/2015)... Cary, NC (PRWEB) February 27, 2015 ... nation’s leading cancer research funding organizations, is excited to ... varied ways to participate and many long-standing partnerships highlight ... cancer and focus on expanding ways for all to ... cash donations to cutting-edge cancer research, The V Foundation ...
(Date:2/27/2015)... 2015 According to court documents, Donna ... June 25, 2013 and underwent a procedure during which ... mouth. Because the duodenoscope allegedly had not been ... “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A lawsuit ... County on behalf of Ms. Pirolli alleging that Lutheran ...
Breaking Medicine News(10 mins):Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 2Health News:Study Finds That Cycling Increases Risk For Prostate Cancer 3Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 2Health News:Conference on Mesothelioma Co-Hosted with National Cancer Institute 3Health News:Pipette.com Announces Limited Time Offer of 24% Off List Price on the Vortex-Genie 2 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... The next time you take aspirin for a headache, ... similar to aspirin, is found in willow tree bark ... defense against pathogens. By mimicking the chemical production processes ... and engineer many important alkaloid drug products, including caffeine, ...
... shot Depo Provera offers a convenient alternative for women who ... research from Arizona State University has shown the shot actually ... medroxyprogesterone acetate (MPA), the hormone active in Depo Provera and ... rodents. The study is currently in press in the journal ...
... HealthDay Reporter , MONDAY, Oct. 31 (HealthDay News) ... report feeling happy and content live longer than others. ... longer life, and the study authors also found that high ... off people,s lives. Still, "the study therefore points ...
... 1 (HealthDay News) --,Pregnant women who have trouble sleeping ... trimesters are more likely to deliver prematurely, according to ... trimester, however, were not associated with increased chances of ... be a connection between sleep and preterm labor, although ...
... PLAINS, N.Y. -- Preterm birth rates improved in almost every ... change was more than 10 percent, according to the March ... three-year improvement in the U.S. preterm birth rate means that ... and spared the risk of life-long health consequences of an ...
... in the November issue of the Journal of ... on the management of incidental findings found on body ... found that is unrelated to the present illness and ... have improved radiologists, ability to identify small or subtle ...
Cached Medicine News:Health News:Plant researchers locate transporter used for nicotine metabolism 2Health News:Hormone in birth control shot linked to memory loss 2Health News:Hormone in birth control shot linked to memory loss 3Health News:Could Happy Lives Be Longer Lives? 2Health News:Could Happy Lives Be Longer Lives? 3Health News:Poor Sleep Might Be Linked to Preterm Labor 2Health News:Preterm birth rate shows three year improvement in most states 2
... etched into the gel tray which casts a ... cables, three 7x10 cm gel trays, 4 aluminum ... The Chameleon can accomodate up to five combs ... of 120 samples with a 2.5 cm path ...
... of a Separation-Control unit for system control ... gel staining. The optional PhastTransfer Kit quickly ... unit. Electrophoresis is performed on a thermostatic ... 0 to +70 C. Multi-step programming capability ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
... 2000 apparatus and ready-to-use gels are the ... of nucleic acids by submerged gel electrophoresis. ... system, offering full compatibility and optimal performance, ... SEA 2000 and a unique staining tray, ...
Medicine Products: